Arimoclomol (INN originally codenamed BRX-345 which is a citrate salt formulation of BRX-220) is an experimental drug developed by CytRx Corporation a biopharmaceutical company based in Los Angeles California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS).
This page contains content from the copyrighted Wikipedia article "Arimoclomol"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
